Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC
Yilin C. Neeley, Kevin T. McDonagh, Willem W. Overwijk, Nicholas P. Restifo, Martin G. SandaVolume:
53
Year:
2002
Language:
english
Pages:
9
DOI:
10.1002/pros.10136
File:
PDF, 161 KB
english, 2002